Helping you detect, treat and manage arthritis

Survey: Help inform the FLARE-OA international project team

University of Lorraine logoThe aim of this survey is to create a tool for the detection of a flare in osteoarthritis of lower limbs that occurred in the past 4 weeks. 

Dear Sir/Madame,

The Outcome Measures in Rheumatology (OMERACT) and Osteoarthritis Research Society International (OARSI) are inviting you to participate in a Delphi survey of the “FLARE-OA” research project entitled “Development and validation of a tool for the detection of flare in osteoarthritis of the lower limbs”.

The “FLARE-OA” project is led by researchers at the University of Lorraine in France and aims to define flare in osteoarthritis (OA). The research team needs to know what patients think is important to consider to define OA flare. The aim of this survey is to create a tool for the detection of a flare in osteoarthritis of lower limbs that occurred on the past 4 weeks.

There is no right or wrong answer in this Delphi survey. Your responses should be based on your own experience and knowledge on the subject.

If you wish to participate in this survey, please:

  1. Register through a unique link, providing your first and last name, and email address: http://enquetes.univ-lorraine.fr/index.php/13432?newtest=Y
  2. Once you register, a link to the questionnaire/survey will be sent to your email account asking you to complete the FLARE-OA FIRST ROUND survey

The survey will take approximately 10 minutes to complete and should not exceed 15 minutes when connected to our site. You have the possibility to answer the survey sequentially (save and reload your ongoing answer). Please provide a response within 3 weeks.

Your participation is very important to the international research team! We thank you in advance for your kind cooperation.

Sincerely,

The FLARE-OA international project team

Francis Guillemin (co-PI), David Hunter (co-PI), Gillian Hawker, Lyn March, Bruno Fautrel, Claudia Rutherford, Elisabeth Spitz, Camille Ricatte, Amandine Schoumacker, Laetitia Ricci-Boyer, Marita Cross, Annica Barcenilla-Wong, Joanna Makovey, Hema Umapathy, Hakima Manseur

Everything you need to know about the shingles vaccine (Shingrix®) if you have inflammatory arthritis or are on a biologic

Image of files and envelops

What is shingles?

Shingles (Herpes Zoster) is an infection that causes a painful skin rash and can lead to a variety of more complex, serious conditions. Shingles is caused by the varicella zoster virus (VZV), the same virus that causes chickenpox. VZV can stay in the nerve cells of an individual long after they recover from chickenpox. The virus may lay dormant for decades, and then reactivate and cause shingles when the individual’s immune system is more weak.

Individuals over the age of 50 have an increased risk of developing shingles as well as anyone who has a compromised immune system. Many people with inflammatory arthritis have a compromised immune system due to taking medications that partially or completely suppress the immune response of an individual.

What is different about Shingrix®?

Shingrix® is not a live vaccine, so individuals cannot develop shingles from the vaccine. Another shingles vaccine, called Zostavax®, is not suitable for individuals with a compromised immune system because it is a live vaccine.

Who should receive Shingrix®? Continue reading

Reminder: Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Did you know that ankylosing spondylitis affects up to 1 in 200 people?

Picture of spine and hip areaAnkylosing spondylitis (AS) is one of the most common types of inflammatory arthritis. It is estimated to affect up to 1 in 200 people.

Ankylosing spondylitis primarily affects the spine, but can also involve the hips, knees, shoulders, and rib cage. The most common symptom of AS is long-term back pain, along with spinal stiffness in the morning or after a long period of rest (this is the main reason why AS is often mis-diagnosed as ordinary “low back pain”).

Unlike in many other forms of arthritis where women are most affected, three out of four people diagnosed with ankylosing spondylitis are men. It tends to strike in the prime of life; while it can strike at any age, it is most common in people between ages 15 and 40. While it has no known cure, it is treatable; with the proper care, people who are diagnosed with AS can lead full, productive lives.

Diagnosis of ankylosing spondylitis

Continue reading

SPINACH 2-project: SupPortIng seNiors And Caregivers to stay mobile at Home

SPINACH 2-project: SupPortIng seNiors And Caregivers to stay mobile at Home

Participants sought for interview/focus group about online module with options on how to stay independent at home when aging

A picture of seniors in a fieldDecisions about how to stay independent at home are difficult ones for seniors, and we often hear that they do not know what their options are to do so.

We have created an online module (webpage) for seniors and caregivers who are facing decisions (with their health professionals) about how to stay independent at home which could be optimized with your feedback!

Continue reading

You’re invited! Free 2017 Calgary Ankylosing Spondylitis & Psoriatic Arthritis Public Information Forum

AS and PsA Forum BannerJoin guest speakers for a free information session to learn more about ankylosing spondylitis and psoriatic arthritis and how to effectively manage these conditions.

Date: Saturday, November 18, 2017
Time: 8:30 am-12:30 pm
Speaker presentations start at 9:00 am

Location:
WINSPORT Multi-purpose Room
88 Canada Olympic Road SW
Calgary, Alberta, T3B 5R5

To register online, please click here or email execdirector@spondylitis.ca or phone (705) 715-2162. On-site registration opens at 8:30 am. Refreshments will be served.

The following topics will be discussed:
Disease overview & diagnosis
Treatment options
What’s new and on the horizon
Pain management
Non-pharmacologic treatment

Guest speakers:
Dr. Diane Mosher (Rheumatologist)
Dr. Olga Zouzina (Rheumatologist)
Carolyn Johns (Physiotherapist)
Alex Charlton (pharmacist)
Patient Speaker

Call for patient input on tocilizumab (Actemra®) for giant cell arteritis

Stickman with megaphone calling for patient inputCall for patient input on tocilizumab (Actemra®) for giant cell arteritis

Do you have giant cell arteritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of giant cell arteritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis?

Stickman with megaphone calling for patient inputCall for patient input on biosimilar infliximab (Merck) for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis? We need your valuable input

Health Canada defines biosimilars as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Remicade®).

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The originator biologic, or reference product, is infliximab (Remicade®).

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on biosimilar etanercept

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on biosimilar etanercept (Erelzi) for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis and rheumatoid arthritis

Biosimilar etanercept (Erelzi) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide your input on biosimilar etanercept for the treatment of ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). You can give input if you are a B.C. resident and have AS, JIA or RA, a caregiver to someone with AS, JIA or RA, or if your group represents people who live with AS, JIA or RA.
Continue reading

Throwback Lupus – What was the state of lupus in 2010?

Slide image with butterfly to represent lupusIn honour of Lupus Awareness Month, the Arthritis Broadcast Network is doing a throwback coverage on lupus. The coverage highlights Arthritis Research Canada and Arthritis Consumer Experts’ coverage of the 9th International Congress on Systemic Lupus Erythematous, Vancouver 2010 (“Lupus 2010”). The event was held in Vancouver, British Columbia, Canada in June, 2010. Hundreds of world leading researchers, healthcare professionals, and individuals living with systemic lupus erythematosus (SLE) learned about the current state of the science in SLE and future opportunities in lupus research, education and care.

The objectives of the Lupus 2010 were to: Continue reading